In this article, we will look at the 11 Best Large Cap Value Stocks to Buy Now.
On September 26, Jeremy Siegel, Wharton professor emeritus and WisdomTree senior economist, appeared on CNBC’s ‘Closing Bell’ to talk about the latest PCE report, whether the Fed should deemphasize inflation, and more.
The week’s econ data, according to CNBC, showed that jobless claims were the lowest since mid-July, Q2 GDP experienced the highest growth since Q3 2023, and the August durable goods crushed estimates. In addition, the PCE prices were in line with expectations.
READ ALSO: Stocks On The Rise: 12 Best Stocks to Invest in Right Now and 12 Affordable Biotech Stocks to Invest In Now.
Siegel stated that all forecasters have now raised their GDP estimates for Q3. With tame inflation and stronger real growth, he considers all these factors to be good signs for the stock market.
While he does expect the tariffs to cause a bump in inflation, he also thinks that the Fed has to look beyond that, primarily because tariffs are like a tax, and that is not a sign of too much demand for goods in the economy. According to him, that is what the Fed has to look out for.
With these trends in view, let’s look at the best large cap value stocks to buy now.
Our Methodology
We used stock screeners to make a list of value stocks with a market cap between $10 billion and $200 billion and a forward P/E below 15. We then selected the top 11 stocks with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.
Note: All data was sourced on September 28.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Large Cap Value Stocks to Buy Now
11. Chubb Limited (NYSE:CB)
Forward P/E: 12.96
Market Cap: $111.91 billion
Number of Hedge Fund Holders: 61
Chubb Limited (NYSE:CB) is one of the best large cap value stocks to buy now. On September 19, Raymond James analyst Gregory Peters reiterated a Buy rating on Chubb Limited (NYSE:CB) and set a price target of $340.00.
Chubb Limited (NYSE:CB) reported a net income of $2.97 billion in its fiscal Q2 2025 results, up 33.1%. Core operating income for the quarter reached a record $2.48 billion, up 12.9%.
Management also reported that the P&C net premiums written for the quarter were $12.39 billion, up 5.2%, or 5.8% in constant dollars.
Chubb Limited (NYSE:CB) provides commercial and personal property and casualty insurance, personal accident and health (A&H), life insurance, and more.
The company’s operations are divided into the following segments: North America Commercial Property and Casualty (P&C) Insurance, North America Personal P&C Insurance, North America Agricultural Insurance, Overseas General Insurance, Global Reinsurance, and Life Insurance.
10. Amgen Inc. (NASDAQ:AMGN)
Forward P/E: 12.95
Market Cap: $146.96 billion
Number of Hedge Fund Holders: 62
Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00.
The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.
Management reported that the planned investment is anticipated to create around 750 jobs, and would support increased drug production at its biologics manufacturing facility in Juncos along with integrating “innovative advanced technologies throughout the operations process”.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.
9. The PNC Financial Services Group, Inc. (NYSE:PNC)
Forward P/E: 13.08
Market Cap: $80.07 billion
Number of Hedge Fund Holders: 66
The PNC Financial Services Group, Inc. (NYSE:PNC) is one of the best large cap value stocks to buy now. On September 25, UBS analyst Erika Najarian maintained a Hold rating on the PNC Financial Services Group, Inc. (NYSE:PNC) and set a price target of $28.25.
In other news, The PNC Financial Services Group, Inc. (NYSE:PNC) announced on September 8 that it signed a definitive agreement to acquire FirstBank Holding Company, including its banking subsidiary FirstBank, headquartered in Lakewood, CO.
Management reported that FirstBank has $26.8 billion in assets as of June 30 and operates 95 branches, offering commercial and retail banking services across Arizona and Colorado.
The PNC Financial Services Group, Inc. (NYSE:PNC) provides financial services. Its operations are divided into the following segments: Retail Banking, Corporate and Institutional Banking, Asset Management Group, and Other.
8. Bristol-Myers Squibb Company (NYSE:BMY)
Forward P/E: 6.77
Market Cap: $89.80 billion
Number of Hedge Fund Holders: 67
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target.
Bristol-Myers Squibb Company (NYSE:BMY) reported $12.3 billion in revenues in fiscal Q2 2025, with growth portfolio revenues of $6.6 billion, up 18%.
GAAP EPS for the quarter was $0.64, and non-GAAP EPS was $1.46.
Bristol-Myers Squibb Company (NYSE:BMY) also raised its 2025 revenue guidance to the range of ~$46.5 billion to $47.5 billion, and updated its non-GAAP EPS range to $6.35 to $6.65.
Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.
7. CVS Health Corporation (NYSE:CVS)
Forward P/E: 11.9
Market Cap: $96.10 billion
Number of Hedge Fund Holders: 71
CVS Health Corporation (NYSE:CVS) is one of the best large cap value stocks to buy now. Bank of America Securities analyst Allen Lutz maintained a Buy rating on CVS Health Corporation (NYSE:CVS) on September 25 and set a price target of $89.00.
CVS Health Corporation (NYSE:CVS) reported $98.9 billion in total revenues for fiscal Q2 2025, up 8.4% compared to the prior year period.
GAAP diluted EPS for the quarter was $0.80, and adjusted EPS was $1.81. CVS Health Corporation (NYSE:CVS) also generated year-to-date cash flow from operations of $6.5 billion.
CVS Health Corporation (NYSE:CVS) is a health solutions company that operates in four segments: healthcare benefits, health services, pharmacy & consumer wellness, and corporate/other.
6. Gilead Sciences, Inc. (NASDAQ:GILD)
Forward P/E: 13.84
Market Cap: $139.09 billion
Number of Hedge Fund Holders: 71
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), keeping the associated price target the same at $143.00.
The analyst based the optimistic rating on Gilead Sciences, Inc.’s (NASDAQ:GILD) positive outlook and potential growth, reasoning that a notable endorsement is the recent update from the US CDC recommending the company’s Yeztugo for HIV pre-exposure prophylaxis (PrEP).
Similarly, JPMorgan analyst Chris Schott raised the firm’s price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $145 from $135 on September 16, keeping an Overweight rating on the shares.
Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.
Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.
5. Pfizer Inc. (NYSE:PFE)
Forward P/E: 7.68
Market Cap: $135.09 billion
Number of Hedge Fund Holders: 83
Pfizer Inc. (NYSE:PFE) is one of the best large cap value stocks to buy now. On September 23, Bank of America Securities analyst Tim Anderson maintained a neutral stance on Pfizer Inc. (NYSE:PFE), giving the stock a Hold rating with a $28 price target.
The analyst supported the rating with the company’s financial outlook and strategic moves, stating that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera is a notable and positive step in entering the obesity market.
However, Anderson added that the acquisition’s full potential is contingent on several pipeline-related milestones, and the deal is still subject to shareholder approval and other conditions.
Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.
4. Merck & Co., Inc. (NYSE:MRK)
Forward P/E: 8.8
Market Cap: $196.22 billion
Number of Hedge Fund Holders: 92
Merck & Co., Inc. (NYSE:MRK) is one of the best large cap value stocks to buy now. Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Co., Inc. (NYSE:MRK) on September 25 without assigning a price target.
Merck & Co., Inc. (NYSE:MRK) reported $15.8 billion in total worldwide sales in fiscal Q2 2025, down 2% compared to fiscal Q2 2024, both nominally and excluding the impact of foreign exchange.
GAAP EPS for the quarter was $1.76, while non-GAAP EPS was $2.13. Management reported that GAAP and non-GAAP EPS include “a charge of $0.07 per share for closing of Hengrui Pharma License Agreement”.
Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.
Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.
3. The Progressive Corporation (NYSE:PGR)
Forward P/E: 13.26
Market Cap: $142.73 billion
Number of Hedge Fund Holders: 99
The Progressive Corporation (NYSE:PGR) is one of the best large cap value stocks to buy now. On September 25, TD Cowen analyst Andrew Kligerman maintained a Hold rating on The Progressive Corporation (NYSE:PGR) and set a price target of $266.00.
In its August results, The Progressive Corporation (NYSE:PGR) reported a net income of $1.220 billion compared to $935 million in August 2024.
The Progressive Corporation (NYSE:PGR) is an insurance holding company that provides residential property insurance, personal and commercial auto insurance, and other specialty property-casualty insurance and related services. The company operates through the Personal Lines, Commercial Lines, and Property segments.
2. Citigroup Inc. (NYSE:C)
Forward P/E: 13.54
Market Cap: $190.38 billion
Number of Hedge Fund Holders: 102
Citigroup Inc. (NYSE:C) is one of the best large cap value stocks to buy now. TD Cowen analyst Steven Alexopoulos reiterated a Hold rating on Citigroup Inc. (NYSE:C) on September 25, setting a price target of $95.00.
The same day, Citigroup Inc. (NYSE:C) reported that it is collaborating with Dandelion to enable “near-instant, full-value cross-border payments directly into digital wallets” across the world, employing Dandelion’s extensive digital wallet network and Citigroup Inc.’s (NYSE:C) WorldLink® Payment Services.
Management reported that the collaboration will launch in Indonesia, the Philippines, Colombia, and Bangladesh, bolstering the company’s offering and facilitating faster and more cost-effective business-to-consumer payments.
Headquartered in New York, Citigroup Inc. (NYSE:C) provides financial products and services. Its operations are divided into the following segments: Services, Markets, Banking, Wealth, US Personal Banking (USPB), and All Other.
1. Capital One Financial Corporation (NYSE:COF)
Forward P/E: 12.7
Market Cap: $143.28 billion
Number of Hedge Fund Holders: 132
Capital One Financial Corporation (NYSE:COF) is one of the best large cap value stocks to buy now. On September 25, Wells Fargo analyst Donald Fandetti maintained a Buy rating on Capital One Financial Corporation (NYSE:COF) and set a price target of $265.00.
Capital One Financial Corporation (NYSE:COF) announced a net loss of $4.3 billion, or $8.58 per diluted common share, for fiscal Q2 2025, compared with net income of $1.4 billion, or $3.45 per diluted common share, in fiscal Q1 2025.
Adjusted net income for the quarter was $5.48 per diluted common share.
Capital One Financial Corporation (NYSE:COF) is a financial holding company that provides financial products and services. The company’s operations are divided into the following segments: Credit Card, Consumer Banking, and Commercial Banking.
While we acknowledge the potential of COF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COF and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
